Quick answers
- What is Nintedanib used for?
- The FDA-approved label (Ofev, Boehringer Ingelheim Pharmaceuticals, Inc., November 20, 2025) says: “OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) 1.1 Idiopathic Pulmonary Fibrosis OFEV is indicated for the treatment of adults with …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Nintedanib have a boxed warning?
- No. None of the 12 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Nintedanib?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Nintedanib been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Nintedanib?
- 12 companies list prescription products of Nintedanib in the FDA NDC Directory, including AvKARE, Sandoz Inc and Edenbridge Pharmaceuticals LLC..
What Nintedanib is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) 1.1 Idiopathic Pulmonary Fibrosis OFEV is indicated for the treatment of adults with …
— FDA label: Ofev, Boehringer Ingelheim Pharmaceuticals, Inc., effective November 20, 2025. Read the full label on DailyMed →
The FDA has 12 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 12 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule |
|---|---|
| Route | Oral |
| Prescription products | 24 in the FDA NDC Directory |
| Brand names | Ofev |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| nintedanib esylate 150 mg capsule | Generic | $12.06 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- AvKARE2 products
- Sandoz Inc2 products
- Edenbridge Pharmaceuticals LLC.2 products
- Epic Pharma, LLC2 products
- Dr. Reddy's Laboratories Inc.2 products
- Golden State Medical Supply, Inc.2 products
- Macleods Pharmaceuticals Limited2 products
- Cipla USA Inc.2 products
- Boehringer Ingelheim Pharmaceuticals, Inc.2 products
- Glenmark Pharmaceuticals Inc., USA2 products
- Exelan Pharmaceuticals Inc.2 products
- Apotex Corp.2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA205832 OFEV | Boehringer Ingelheim | October 15, 2014 | 13, latest October 11, 2024 2024: Labeling · 2024: Labeling · 2022: Labeling |
Generic approvals (8)
- ANDA212609Cipla · April 2, 2026
- ANDA216915Sandoz · April 2, 2026
- ANDA219227Apotex · April 2, 2026
- ANDA219283DR Reddys · April 2, 2026
- ANDA219819Dexcel · April 2, 2026
- ANDA212555Glenmark Pharms Ltd · July 9, 2026
- ANDA218472Humanwell Puracap · July 9, 2026
- ANDA219926Macleods Pharms · August 3, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1592742, 1592748, 1592750, 1592752 |
|---|---|
| SPL set ID of the quoted label | da1c9f37-779e-4682-816f-93d0faa4cfc9 |
| FDA labels (SPL) | 12 |
| FDA applications | NDA205832, 8 ANDA |
| Active ingredients (FDA) | NINTEDANIB ESYLATE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ofev, Boehringer Ingelheim Pharmaceuticals, Inc., effective November 20, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →